Qingdai Decoction suppresses prostate cancer growth in lethal-stage prostate cancer models

被引:7
作者
Chen, Yanhua [1 ]
Zhou, Qianqian [1 ]
Zhang, Hong [2 ]
Xu, Linfan [3 ]
Lu, Lianheng [1 ]
Shu, Bing [2 ]
Zhou, Lihong [4 ]
Yuan, Fuwen [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai 201203, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Longhua Hosp, 725 Wan Ping South Rd, Shanghai 200032, Peoples R China
[3] Anhui Med Univ, Affiliated Hosp 1, Dept Urol, Hefei, Anhui, Peoples R China
[4] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, Shanghai 201203, Peoples R China
关键词
BIOCHEMICAL RECURRENCE; MORTALITY;
D O I
10.1016/j.jep.2023.116333
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Contemporary therapy for advanced castration-resistant prostate cancer (CRPC) employs reagents such as enzalutamide and abir-aterone acetate targeting the androgen receptor (AR) transcription axis only provide a temporary response and rapidly develop resistance. Additionally, neuroen-docrine prostate cancer (NEPC) is an AR pathway-independent and lethal-stage prostate cancer with no standard therapy. Qingdai Decoction (QDT), a traditional Chinese medicine formula, has various pharmacological activities and was widely used for the treatment of different diseases including prostatitis which may contribute to prostate cancer development.Aim of the study: This study aims to explore the anti-tumor role and potential mechanism of QDT on prostate cancer.Material and methods: CRPC prostate cancer cell models and xenograft mice models were established for research. The effect of TCMs on cancer growth and metastasis were determined by CCK-8, wound-healing assays and the PC3-xenografted mice model. The toxicity of QDT in the major organs was investigated by H&E staining. The compound-target network was analyzed with network pharmacology. The correlation of QDT targets with prostate cancer patient's prognosis was analyzed with multiple prostate cancer patient cohorts. The expression of related proteins and mRNA were detected by western blot and real-time PCR. The gene knockdown was achieved with CRISPR-Cas13 technology.Results: By integrating functional screening, network pharmacology analysis, CRISPR-Cas13 directed RNA targeting, and molecular biology validation in different prostate cancer models and clinical prostate cancer cohorts, we found that Qingdai Decoction (QDT), a Traditional Chinese Medicine, can repress cancer growth in advanced prostate cancer models in vitro and in vivo in an AR independent manner by targeting NOS3, TGFB1, and NCOA2.Conclusion: This study not only identified QDT as a novel drug for lethal-stage prostate cancer treatment but also provided an extensive Integrative research paradigm for investigating the roles and mechanisms of TCMs for the treatment of other diseases.
引用
收藏
页数:10
相关论文
共 43 条
[1]   Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study [J].
Aggarwal, Rahul ;
Huang, Jiaoti ;
Alumkal, Joshi J. ;
Zhang, Li ;
Feng, Felix Y. ;
Thomas, George V. ;
Weinstein, Alana S. ;
Friedl, Verena ;
Zhang, Can ;
Witte, Owen N. ;
Lloyd, Paul ;
Gleave, Martin ;
Evans, Christopher P. ;
Youngren, Jack ;
Beer, Tomasz M. ;
Rettig, Matthew ;
Wong, Christopher K. ;
True, Lawrence ;
Foye, Adam ;
Playdle, Denise ;
Ryan, Charles J. ;
Lara, Primo ;
Chi, Kim N. ;
Uzunangelov, Vlado ;
Sokolov, Artem ;
Newton, Yulia ;
Beltran, Himisha ;
Demichelis, Francesca ;
Rubin, Mark A. ;
Stuart, Joshua M. ;
Small, Eric J. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) :2492-+
[2]   Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes [J].
Aparicio, Ana ;
Logothetis, Christopher J. ;
Maity, Sankar N. .
CANCER DISCOVERY, 2011, 1 (06) :466-468
[3]   Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer [J].
Beltran, Himisha ;
Tagawa, Scott T. ;
Park, Kyung ;
MacDonald, Theresa ;
Milowsky, Matthew I. ;
Mosquera, Juan Miguel ;
Rubin, Mark A. ;
Nanus, David M. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) :E386-E389
[4]   Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy [J].
Brockman, John A. ;
Alanee, Shaheen ;
Vickers, Andrew J. ;
Scardino, Peter T. ;
Wood, David P. ;
Kibel, Adam S. ;
Lin, Daniel W. ;
Bianco, Fernando J., Jr. ;
Rabah, Danny M. ;
Klein, Eric A. ;
Ciezki, Jay P. ;
Gao, Tianming ;
Kattan, Michael W. ;
Stephenson, Andrew J. .
EUROPEAN UROLOGY, 2015, 67 (06) :1160-1167
[5]   Nuclear Receptor Coactivator 2 Promotes Human Breast Cancer Cell Growth by Positively Regulating the MAPK/ERK Pathway [J].
Cai, Mengjiao ;
Liang, Xin ;
Sun, Xiao ;
Chen, Huan ;
Dong, Yiping ;
Wu, Lingzhi ;
Gu, Suxi ;
Han, Suxia .
FRONTIERS IN ONCOLOGY, 2019, 9
[6]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404
[7]   Second generation androgen receptor antagonists and challenges in prostate cancer treatment [J].
Chen, Yanhua ;
Zhou, Qianqian ;
Hankey, William ;
Fang, Xiaosheng ;
Yuan, Fuwen .
CELL DEATH & DISEASE, 2022, 13 (07)
[8]   Anti-endometriosis Mechanism of Jiawei Foshou San Based on Network Pharmacology [J].
Chen, Yi ;
Wei, Jiahui ;
Zhang, Ying ;
Sun, Wenwei ;
Li, Zhuoheng ;
Wang, Qin ;
Xu, Xiaoyu ;
Li, Cong ;
Li, Panhong .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[9]   Eyes on systems pharmacology [J].
Chen, Yu ;
Kern, Timothy S. ;
Kiser, Philip D. ;
Palczewski, Krzysztof .
PHARMACOLOGICAL RESEARCH, 2016, 114 :39-41
[10]   Clinical features of neuroendocrine prostate cancer [J].
Conteduca, Vincenza ;
Oromendia, Clara ;
Eng, Kenneth W. ;
Bareja, Rohan ;
Sigouros, Michael ;
Molina, Ana ;
Faltas, Bishoy M. ;
Sboner, Andrea ;
Mosquera, Juan Miguel ;
Elemento, Olivier ;
Nanus, David M. ;
Tagawa, Scott T. ;
Ballman, Karla V. ;
Beltran, Himisha .
EUROPEAN JOURNAL OF CANCER, 2019, 121 :7-18